Clinical trial · Interventional
High Precision RT For Soft-Tissue Sarcoma
Use of High Precision Radiotherapy in the Management of Soft-Tissue Sarcomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study aims at defining 1) how retroperitoneal sarcomas change over the course of radiotherapy and 2) how radiotherapy affects your well-being. While the investigators know that radiotherapy before surgery is safe and effective, the amount of tumor motion and size change during radiotherapy is unknown. There is also very little information that describes the side-effects of radiotherapy in the treatment of this disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Soft-Tissue Sarcoma | Soft Tissue Sarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Daily Cone Beam CT | Radiation | — | UNRESOLVED |
| Intensity-Modulated Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Follow-up
- description
- Data from these patients will be added to retrospectively gathered data from the PMH radiotherapy data bank (approximately 50 patients). The data collected will be analyzed using descriptive statistics.
- type
- EXPERIMENTAL
- label
- Prospective
- interventionNames
- Radiation: Intensity-Modulated Radiotherapy
- Radiation: Daily Cone Beam CT
Primary outcomes (2)
- measure
- To determine the extent of inter-fractional and intra-fractional movement of the GTV during radiotherapy treatments.
- timeFrame
- 3 years
- description
- To quantify and describe the movement of the tumor during and between radiotherapy treatments using imagings acquired during the course of radiotherapy planning and treatments.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically (histologically or cytologically) proven diagnosis of sarcoma (except for GIST, Ewing's sarcoma and rhabdomyosarcoma) within the retroperitoneum. These include patients with locally recurrent disease * Planned to receive pre-operative radiotherapy * Will undergo a planning CT * Karnofsky Performance Status of ≥ 70 within 28 days prior to study entry * No systemic chemotherapy given prior to pre-operative radiotherapy * Able to provide written, informed consent * Women of childbearing potential and men who are sexually active must practice adequate contraception. Exclusion Criteria: * Tumor pathology of GIST, Ewing's sarcoma or rhabdomyosarcoma * Metastatic disease to the retroperitoneum from a primary sarcoma not originating from the retroperitoneum * Systemic chemotherapy given prior to pre-operative radiotherapy. * Intent on giving chemotherapy ≤ 12 months from the completion of radiotherapy * Inability to undergo a 4D-CT simulation * KPS \< 70 * Unable to provide informed consent * Pregnant women
References
Publications (0)
Data not yet available